RUNX1T1 and neoplasm: The results revealed that the intraperitoneal administration of ETO effectively delayed transplanted tumor growth in H22 tumor-bearing mice with minimal toxicity through modulation of metabolic pathways and gut microbiota, thus indicating the potential of ETO as a therapeutic candidate for tumors.